جستجوی استاد راهنمای دانشگاهی

Nicholas A Vitanzaمشاهده پروفایل

دانشیار

• Pediatric Neuro-Oncology
• Brain Tumor Research
• CAR T Cell Therapy
• +۶ مورد دیگر

Nicholas A Vitanza is an Associate Professor in Hematology/Oncology at Seattle Children's Hospital, where he serves as an Attending Pediatric Neuro-Oncologist in the Cancer and Blood Disorders Center. He is also the Principal Investigator at the Ben Towne Center for Childhood Cancer and Blood Disorders Research and has been on staff since August 2016. Dr. Vitanza directs the Vitanza Lab and serves as the Scientific Director of the Brain Tumor Research Program, overseeing a dedicated research program spanning laboratory work to patient care, and as the CNS CAR T Cell Lead, overseeing CAR T cell trials for brain and spinal cord tumor patients. Dr. Vitanza completed his medical education at the American University of the Caribbean School of Medicine, followed by residency training at the State University of New York at Stony Brook. He then completed fellowships at multiple prestigious institutions including Lucile Salter Packard Children's Hospital-Stanford, New York University Langone Medical Center, and Stanford University School of Medicine. His specialized training in pediatric oncology and neuro-oncology was conducted under renowned mentors including Drs. Bill Carroll, Elizabeth Raetz, and Michelle Monje. Dr. Vitanza's research focuses on developing targeted therapies for children with fatal brain and spinal cord tumors, particularly diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma (DMG), and atypical teratoid rhabdoid tumor (ATRT). His work spans from high-throughput drug screening in patient-derived models to clinical translation, with a particular emphasis on CAR T cell immunotherapies. He has pioneered multiple innovative clinical trials including BrainChild-01 (targeting HER2), BrainChild-02 (targeting EGFR), BrainChild-03 (targeting B7-H3), and BrainChild-04 (multi-antigen targeting). Analysis of Dr. Vitanza's recent publications reveals a strong focus on advancing CAR T cell therapies for pediatric CNS tumors, with particular emphasis on combination approaches, multi-targeting strategies, and addressing treatment-related toxicities. His work bridges basic science discoveries with clinical applications, consistently aiming to translate laboratory findings into novel therapeutic options for children with previously untreatable brain cancers. The publications demonstrate progressive refinement of delivery methods, target selection, and safety profiles of immunotherapies for pediatric brain tumors. R37 MERIT (Method to Extend Research in Time) Award from NIH National Cancer Institute Invited researcher to Cancer Moonshot Brain Tumor Forum at White House (2023) ASPHO award during pediatric oncology fellowship Dr. Vitanza has secured significant NIH funding for his research and has directed multiple clinical trials that have advanced the field of pediatric neuro-oncology. His laboratory work has led to multiple clinical trials, demonstrating a successful translational pipeline from bench to bedside. He has mentored numerous researchers and clinicians in the field of pediatric brain tumor research and treatment. The Vitanza Lab focuses on creating treatment-naïve biopsy-derived patient-derived DIPG/DMG models, discovering targetable molecular and immunologic vulnerabilities in these tumors, and translating these findings into innovative new clinical trials. The lab collaborates extensively with other research groups at Seattle Children's Hospital and beyond, forming a comprehensive research ecosystem dedicated to curing childhood brain cancers.

Friedhelm Hildebrandtمشاهده پروفایل

استاد

• Pediatric Nephrology
• Genetic Kidney Diseases
• Recessive Single-Gene Disorders
• +۷ مورد دیگر

Friedhelm Hildebrandt is a Professor of Pediatrics and Ophthalmology at Harvard Medical School and a leading researcher in pediatric nephrology at Boston Children's Hospital. As an investigator of the Howard Hughes Medical Institute (HHMI), he directs a highly productive research laboratory focused on identifying the genetic causes of kidney diseases in children. His work bridges basic science and clinical applications, with a particular emphasis on translating genetic discoveries into improved diagnostics and potential treatments. Dr. Hildebrandt received his MD from Marburg University Medical School and completed internships and residency at Marburg University Medical School and Heidelberg University in Germany, as well as Middlesex Hospital Medical School in London. He furthered his training with postdoctoral research at Yale University. His educational background has provided a strong foundation for his career in both clinical medicine and research. His research primarily focuses on the identification and functional characterization of recessive single-gene causes of kidney diseases in children. His laboratory has identified more than 30 novel kidney disease genes, significantly advancing our understanding of genetic kidney disorders. He has developed efficient methods for gene identification using whole exome resequencing and other highly-parallel sequencing techniques. Since 2000, Dr. Hildebrandt has performed 'experimental' mutation analysis in single-gene renal diseases worldwide for more than 5,000 pediatric patients, establishing himself as a global authority in the field. Analysis of his recent publications reveals a consistent focus on identifying novel genetic causes of kidney diseases, with particular emphasis on congenital anomalies of the kidney and urinary tract (CAKUT) and steroid-resistant nephrotic syndrome. His work increasingly incorporates advanced genomic techniques like trio exome sequencing and copy number variant analysis, while also exploring the functional consequences of genetic variants through animal models and molecular studies. A notable trend is the growing emphasis on translating genetic findings into potential therapeutic approaches, as evidenced by studies examining treatment response to anti-proteinuric therapies based on genetic profiles. E. Mead Johnson Award in Pediatric Research (APS/SPR) Howard Hughes Medical Institute (HHMI) Investigator Member of the American Association of Physicians (AAP) Member of the German Academy of Sciences (Leopoldina) Dr. Hildebrandt has secured substantial research funding to support his investigations into the genetic basis of pediatric kidney diseases. His laboratory serves as a training ground for numerous postdoctoral fellows and graduate students, many of whom have gone on to establish independent research careers. The lab maintains active collaborations with researchers worldwide, facilitating the identification of rare genetic variants through international patient cohorts. His work has established critical connections between DNA damage repair pathways and chronic kidney failure, opening new avenues for potential therapeutic interventions. Current research directions include developing quantitative phenotyping methods for animal models to support gene replacement studies and exploring the potential for genotype-guided treatments for children with genetic kidney diseases.

• Cancer Genomics
• Genome Instability
• DNA Repair
• +۷ مورد دیگر

Fran Supek is a Professor at the University of Copenhagen's Faculty of Health and Medical Sciences, where he leads the Genome Data Science laboratory at the Biotech Research & Innovation Centre (BRIC). He also maintains a research group at the IRB Barcelona. Supek is the Principal Investigator of ERC Starting and ERC Consolidator projects, an EMBO Young Investigator, and holds an ICREA tenured professor position (currently on leave). Dr. Supek obtained his PhD in Molecular Biology in 2010 from the University of Zagreb, followed by postdoctoral training at the Centre for Genomic Regulation (CRG) as a Marie Curie fellow. He established his independent laboratory at IRB Barcelona in 2017 as a "Ramón y Cajal" tenure-track fellow, and expanded to BRIC in 2024. His research focuses on statistical genomics and machine learning approaches to study genome stability mechanisms, particularly through analysis of mutation patterns in cancer. The Genome Data Science lab performs large-scale bioinformatic studies of multi-omic data from human tumors, populations, and metagenomes. Key research areas include DNA repair mechanisms, mRNA synthesis and turnover pathways, genetic interactions in cancer genomes, and machine learning approaches for inferring gene function from genomic data. Analysis of Supek's recent publications reveals a strong emphasis on cancer genomics, with particular focus on mutational signatures, DNA repair deficiencies, and the application of artificial intelligence to genomic data analysis. His work spans from fundamental mechanisms of genome instability to translational applications in cancer diagnosis and treatment. ERC Starting Grant recipient ERC Consolidator Grant recipient EMBO Young Investigator ICREA tenured professor (on leave) As Principal Investigator of multiple ERC projects, Supek leads a research program with significant funding for innovative genomic research. His laboratory at BRIC and IRB Barcelona conducts interdisciplinary research combining computational approaches with experimental validation to address fundamental questions in genome biology and cancer evolution. The Genome Data Science lab maintains active collaborations across multiple institutions, with research spanning statistical genomics, machine learning applications in bioinformatics, and experimental validation of computational predictions in cancer biology.